Letrozole Teva

Letrozole, the active ingredient in Letrozole Teva, is an aromatase inhibitor presented as a tablet for oral use. It is used to treat hormone‑receptor positive breast cancer in postmenopausal women. GNH USA supplies Letrozole Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozole is an aromatase inhibitor indicated for hormone‑receptor positive breast cancer in postmenopausal women.

- Early‑stage breast cancer: reduces risk of recurrence after surgery. - Advanced/metastatic breast cancer: slows disease progression and improves survival. - Adjuvant therapy after tumor removal: helps prevent cancer return.

Letrozole may cause a range of adverse reactions.

Common Side Effects: - Hot flashes: transient episodes of increased warmth. - Arthralgia: joint pain or stiffness. - Fatigue: persistent tiredness. - Nausea: mild to moderate upset stomach. - Headache: occasional throbbing pain. - Osteoporosis: reduced bone mineral density.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins. - Severe liver injury: marked elevation of hepatic enzymes. - Cardiac arrhythmia: irregular heart rhythm. - Severe allergic reaction: rash, swelling, or breathing difficulty. - Hyperglycemia: significant rise in blood glucose levels.

Before initiating Letrozole therapy, consider the following precautions.

- Bone health assessment: evaluate risk of osteoporosis and consider calcium/vitamin D supplementation. - Liver function monitoring: check baseline enzymes and repeat periodically. - Cardiovascular risk evaluation: assess history of thromboembolic events. - Drug interactions review: avoid concomitant use of strong CYP2A6 inhibitors. - Pregnancy and lactation: contraindicated; ensure effective contraception. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Letrozole can interact with several medicines; monitoring is essential.

Major Interactions (Avoid): - Strong CYP2A6 inhibitors (e.g., fluvoxamine): may increase letrozole exposure. - Estrogen‑containing therapies (e.g., hormone replacement): antagonize therapeutic effect.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may alter coagulation parameters. - CYP3A4 inducers (e.g., rifampin): may reduce letrozole plasma levels. - Tamoxifen: concurrent use may affect efficacy of both agents.